Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BT09

UPID:
CNPY3_HUMAN

ALTERNATIVE NAMES:
CTG repeat protein 4a; Expanded repeat-domain protein CAG/CTG 5; Protein associated with TLR4; Trinucleotide repeat-containing gene 5 protein

ALTERNATIVE UPACC:
Q9BT09; O15412; Q0P6I2; Q8NF54; Q8WTU8; Q9P0F2

BACKGROUND:
The Protein canopy homolog 3, with alternative names such as CTG repeat protein 4a and Protein associated with TLR4, is integral to immune system functionality. It serves as a specific co-chaperone for HSP90B1, necessary for the correct folding of Toll-like receptors, which are crucial for immune response initiation. This protein's unique role underscores its importance in maintaining immune system balance.

THERAPEUTIC SIGNIFICANCE:
Linked to Developmental and epileptic encephalopathy 60, a disorder marked by severe epilepsy and cognitive delays, Protein canopy homolog 3's involvement highlights its potential as a target for therapeutic intervention. Exploring its function and the impact of genetic variants could lead to breakthroughs in treatment approaches for this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.